BioNTech SEBNTX
Price (close)
$98.52
Market cap
$24.7B
P/E
—
Revenue (FY)
$2.9B
Net income
-$1.1B
Dividend yield
—
1-year total return
0.4%
Net margin
-39.6%
Revenue growth
4.3%
Debt / equity
—
What BioNTech SE does.
(4) Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig.
clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the
not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $482.3M | $19.0B | $17.3B | $3.8B | $2.8B | $2.9B |
| Net income | $15.2M | $10.3B | $9.4B | $930.3M | -$665.3M | -$1.1B |
| Free cash flow | -$79.5M | $762.2M | $13.2B | $5.1B | -$78.8M | $280.9M |
More on BNTX.
- BioNTech SE summary
- BioNTech SE financial statements
- BioNTech SE key metrics
- BioNTech SE health scores and style box
- BioNTech SE earnings
- BioNTech SE dividends
- BioNTech SE valuation
- BioNTech SE ownership and insiders
- BioNTech SE peers
Figures from BioNTech SE's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.